Department of Obstetrics and Gynecology, University Hospitals of Cleveland, MacDonald Women's Hospital, Case Western Reserve University School of Medicine, Cleveland, and Ms. Medicine, Cincinnati, Ohio.
Corresponding author: Sheryl A. Kingsberg, PhD, Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, OH; email: sheryl.kingsberg@uhhospitals.org.
Financial Disclosure Sheryl A. Kingsberg disclosed that money was paid to her institution from Endoceutics and Palatin Technologies. Money was paid to her from AMAG, Sprout, Palatin Technologies, Therapeutics MD, Pfizer, Endoceutics, Mitsubishi Tanaba NA, Dare, Lupin, Strategic Science Technologies, Emotional Brain, Ovaco, Astellas. She holds stock options in Viveve. Lisa C. Larkin reports receiving funds from AMAG, Therapeutics MD, AMGEN, Proctor and Gamble, and Lupin. James H. Liu disclosed that money was paid to his institution from AbbVie, Bayer, FemaSys, and Allergan. He also received funds from Therapeutics MD, Ferring, AMAG, Bayer, Mitsubishi-Tanaba, and Dare.
This article includes a discussion of off-label treatments for postmenopausal women with hypoactive sexual desire disorder, including systemic testosterone products, none of which are approved for women, and flibanserin and bremelanotide, which are approved only for premenopausal women. Systemic testosterone is also discussed as an off-label treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM). Systemic hormone therapy is discussed as an off-label therapy for treatment of mood disorders in postmenopausal women.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at http://links.lww.com/AOG/B757.
